The company was named among the best long-term performing stocks. UBS raised its price target from $386 to $400, citing continued strength in the medical technology sector, though it maintained a Neutral rating. The CEO described the most recent fiscal year as outstanding. The stock has shown strong multi-year performance, with significant gains over three and five years, leading to investor debate about whether its current share price still offers value or if the opportunity is already reflected in the market.